<DOC>
	<DOCNO>NCT00003464</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat adult newly diagnose primary malignant glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity temozolomide adult newly diagnose glioblastoma multiforme . - Define relationship tumor O6-alkylguanine-DNA alkyltransferase activity tumor response patient . - Define relationship tumor DNA mismatch repair activity tumor response temozolomide . OUTLINE : Patients receive temozolomide orally daily day 1-5 . Treatment course repeat every 28 day . In absence disease progression toxicity , patient receive 4 course treatment prior radiation therapy . After radiation therapy , patient demonstrate partial complete response may receive additional 12 course treatment . Patients follow every 8-12 week 2 year . PROJECTED ACCRUAL : This study accrue 50 patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , newly diagnose , supratentorial malignant glioblastoma multiforme require immediate radiation therapy At least 1 bidimensionally measurable lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 1500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Other : Must neurologically stable No systemic disease No acute infection require intravenous antibiotic No frequent vomit No medical condition would interfere oral medication intake partial bowel obstruction No prior concurrent malignancy except : Surgically cure carcinoma situ cervix Basal squamous cell carcinoma skin HIV negative No AIDSrelated illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent biologic therapy ( growth factor erythropoietin ) Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Concurrent steroid allow ( must stable dose least 1 week prior study ) Radiotherapy : No prior radiation therapy No prior interstitial brachytherapy No prior radiosurgery brain Not require immediate radiation therapy No concurrent radiotherapy Surgery : Recovered effect prior surgery At least 2 week since prior surgical resection Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>